GC 4419

Drug Profile

GC 4419

Alternative Names: GC4419

Latest Information Update: 05 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galera Therapeutics
  • Class Antifibrotics; Antineoplastics; Chemoprotectants; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stomatitis
  • Phase I/II Head and neck cancer; Pancreatic cancer
  • Phase I Unspecified
  • No development reported Fibrosis

Most Recent Events

  • 20 Aug 2018 Galera Therapeutics plans a phase III trial for Stomatitis, in 2018
  • 05 Jul 2018 Efficacy data from a phase IIb trial in Stomatitis released by Galera Therapeutics
  • 03 Jun 2018 Updated efficacy data from a phase I/II trial in Head and neck cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top